Morfinesulfaat Tiofarma (Morphine Sulfate Pentahydrate)

Morphine sulfate pentahydrate, the active ingredient in Morfinesulfaat Tiofarma, is an opioid analgesic presented as an oral dosage form for oral use. It treats moderate to severe pain in adult patients. GNH USA supplies Morfinesulfaat Tiofarma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Morphine sulfate pentahydrate is an opioid analgesic used to manage pain across several clinical contexts. - Acute postoperative pain: provides effective analgesia to reduce postoperative discomfort. - Cancer‑related pain: helps control moderate to severe nociceptive pain associated with malignancy. - Chronic non‑cancer pain: used when other analgesics are insufficient to control persistent severe pain.

Common Side Effects: - Nausea: feeling of sickness often accompanied by an urge to vomit. - Constipation: reduced bowel motility leading to hard stools. - Drowsiness: increased sleepiness or reduced alertness. - Vomiting: expulsion of stomach contents.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure causing dizziness or fainting. - Anaphylactic reaction: severe allergic response with rash, swelling, and airway compromise.

Before prescribing Morfinesulfaat Tiofarma, clinicians should consider several safety measures. - Assess pain severity before initiating therapy: ensure opioid indication is appropriate. - Evaluate patient history for respiratory disorders: monitor closely for breathing difficulties. - Check for concurrent CNS depressants: adjust dose to avoid additive effects. - Consider renal or hepatic impairment: dose may need modification. - Avoid use in patients with known hypersensitivity to morphine: discontinue if reaction occurs. - Store at ambient temperature below 25°C: keep in original container, protect from moisture.

Morphine sulfate can interact with various medications, requiring careful management. Major Interactions (Avoid): - Concomitant use with other opioids: risk of additive respiratory depression. - Benzodiazepines or barbiturates: increased central nervous system depression. - MAO inhibitors: potential for severe hypotension. Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors: monitor for serotonin syndrome. - Anticholinergic agents: may worsen constipation.